Jefferies Global Healthcare Conference in London - GENEDX HOLDINGS CORP
Financial Performance:
- Company is on track to deliver total volume growth near 30% for the year, with Q3 sample sessions up 25%.
- Average Selling Price (ASP) grew mid-single digits sequentially in Q3, exceeding expectations by approximately $100; driven by a 4% improvement in genome collection rates (32% to 36%).
- Gross margin profile remains solidified in the 30s range; the business is currently profitable.
- Sequential business performance improved from Q1 through Q3, despite falling short of initial full-year expectations due to early-year mix shifts and volume volatility.
- Current collection rates sit in the low 30s to 40s, with a long-term target of 70–80% as revenue cycle transformation matures.
- Approximately 88% of commercial lives have active payer coverage for genome testing, though collection rates lag significantly behind coverage availability.
- 62% of claim denials are attributed to administrative and procedural issues rather than medical necessity.
Guidance and Future Outlook:
- Management expects another sequential ASP uptick of approximately $100 in Q4, driven by seasonal benefits, continued revenue cycle progress, and maturation of payer policies like Carillon and state Medicaid programs.
- Revenue cycle transformation implementation is targeted for go-live in Q4 and Q1, which is expected to align sample submission sessions with final report volumes.
- Long-term goal is to bridge the gap between coverage and collection rates, eventually driving revenue growth to converge with and exceed volume growth rates.
- General pediatrics expansion is expected to contribute meaningfully to growth in 2027 and beyond, following a successful early ramp in late 2026.
- NICU segment is projected to grow above the corporate average in fiscal 2026, though a major inflection point for utilization is anticipated further out.
Business Segments and Product Lines:
- Genomics Services: Core business focused on pediatric rare disease diagnosis; experiencing a strategic shift from Exome to Genome sequencing, which is viewed positively for clinical outcomes despite early financial friction.
- General Pediatrics: Commercial expansion included adding roughly 50 specialized sales reps in February; early indicators show strong new account activations and repeat order rates as the team educates physicians on 2025 AAP guidelines for global intellectual developmental delay.
- NICU: Market is 100% cash/institutional pay, avoiding commercial adjudication risks; estimated addressable market is 250,000 tests/year, but current utilization remains in the mid-to-high single digits due to lengthy integration sales cycles.
- Revenue Cycle Management (RCM): A multi-year transformation underway to automate documentation, prior authorization, and payer intelligence, moving away from manual "brute force" processes that previously slowed throughput.
Market and Competitive Landscape:
- Addresses a $30 billion unmet clinical need affecting 1 in 10 Americans with rare diseases, surpassing the cancer market in total patient volume.
- Strategic objective is to "move upstream" in the diagnostic journey, expanding testing access from a narrow cohort of 2,000 expert geneticists to the broader population of general pediatricians.
- Market trend involves a natural migration from Exome to Genome-only testing, with physicians adopting the newer technology while largely remaining with GeneDx.
- 8 out of 10 expert geneticists in the US already order Exome/Genome from GeneDx, leveraging 25 years of trust to expand into primary care settings.
- Competition is minimal regarding the specific mission of ending the "diagnostic odyssey" for children, though the company faces challenges from disparate payer policies (nearly 1,000 unique rule sets).
Risks and Challenges:
- Payer Policy Volatility: Disparate documentation requirements and medical necessity criteria across payers create significant friction, requiring continuous manual intervention and slowing the order-to-result cycle.
- Operational Trade-offs: Early RCM improvements required slowing the testing process to secure prior authorization, degrading short-term customer experience and causing a divergence between sample submission and report completion rates.
- Revenue Gap: A substantial disconnect exists between high payer coverage rates (~90%) and low actual cash collection rates (30–40%), which must be bridged to realize margin leverage.
- Long Sales Cycles: particularly in the NICU sector, where embedding tests into hospital Standard Operating Procedures (SOPs) and protocols takes significant time and effort.
- Cannibalization Risk: Management views this as a non-issue for the foreseeable future, citing the vast size of the addressable market and the distinct roles of generalists versus specialists.
Management Commentary and Tone:
- Tone was confident and transparent, acknowledging early-year execution challenges while emphasizing strong underlying trends and sequential improvements.
- Management expressed pride in the company's trajectory and the critical nature of its mission to reduce the average age of rare disease diagnosis from 14 years down to 5 years, with a goal of diagnosis at birth by the end of the decade.
- Kevin (CEO) and the team demonstrated a pragmatic approach, accepting short-term volume/ASP volatility to secure long-term margin expansion and sustainable growth.
- Confidence is high in the new RCM leadership and the ability to execute the technological transformation required to automate payer compliance.
Analyst Questions and Answers:
- ASP Drivers: Q3 ASP growth was equally split between product mix and collection rate improvements; Q4 guidance relies on similar factors plus seasonal uplifts and policy maturation.
- Volume vs. Sessions: The 3% divergence between volume and sample sessions in Q3 was a deliberate result of RCM holds; convergence is expected in Q4/Q1 once automated workflows launch.
- Payer Coverage vs. Collections: Management clarified that coverage rates will eventually converge with collection rates, but current disparities are due to the complexity of 1,000+ unique payer rule sets rather than lack of coverage.
- General Pediatrics Cannibalization: Analysts asked if new pediatric orders would cannibalize expert geneticist business; Management replied the market is too large for this to occur for decades.
- NICU Inflection: Management noted no single "gating factor" for NICU growth; adoption varies by hospital system based on their willingness to rewrite protocols and embed new testing into high-intensity clinical workflows.
Other Key Points:
- The average age of diagnosis for children with rare disease has already been reduced from 14 to 5 years over the last 11 years.
- The company is investing in a "payer intelligence engine" using AI to scrape medical records and automate documentation, aiming to make the pre-analytical process frictionless for physicians.
- Exome testing still comprises ~75% of the total portfolio but carries higher gross margins than Genome; the RCM transformation will eventually benefit the entire portfolio including multi-gene panels.
- The company aims to move toward potential genomic newborn screening in the long term, a market of 3.6 million live births annually.
- Company
- GENEDX HOLDINGS CORP
- Keywords
- GENEDX HOLDINGS CORP